Oral Iron Supplementation Guidelines for Children

Formulation Selection

Ferrous sulfate is the preferred oral iron formulation because it is the most cost‑effective option and has demonstrated efficacy in pediatric iron deficiency anemia. 1
No oral iron formulation has shown superiority over others in terms of effectiveness, indicating that choice can be based on availability and cost. 1
Alternative formulations such as ferrous gluconate or ferrous fumarate provide no clinical advantage and are generally more expensive than ferrous sulfate. 1

Iron should be administered once daily at most to achieve adequate absorption while minimizing inconvenience. 1
An every‑other‑day dosing schedule may be better tolerated and yields absorption rates comparable to daily dosing. 1
Switching to every‑other‑day dosing can reduce gastrointestinal side effects without compromising efficacy. 1

Co‑administration of vitamin C (e.g., orange juice or a vitamin C supplement) enhances oral iron absorption. 1

If gastrointestinal side effects from ferrous sulfate are intolerable, clinicians can either adopt an every‑other‑day regimen or switch to alternative formulations such as bis‑glycinate iron, which is associated with a lower side‑effect rate (~6%). 1

Intravenous iron is recommended when a child cannot tolerate oral iron despite dosing adjustments, fails to show ferritin improvement after an adequate oral trial, or has conditions that impair oral iron absorption (e.g., malabsorption syndromes, inflammatory bowel disease). 1

To provide 60 mg of elemental iron, prescribe 300 mg of ferrous sulfate (approximately 20 % elemental iron by weight). 1
Standard liquid ferrous sulfate preparations contain 15 mg elemental iron per mL (equivalent to 75 mg ferrous sulfate per mL). 1

Continue oral iron supplementation for approximately three months after hemoglobin has returned to normal to fully replenish iron stores. This recommendation is based on the guidance from the Gut journal (2011) and reflects a standard practice to prevent relapse. 2

Intravenous iron should not be used as first‑line therapy for iron‑deficiency anemia in children; it is reserved for cases where oral iron is contraindicated, poorly tolerated, or ineffective after an adequate trial. This position is supported by evidence from two publications in Clinical Nutrition (2018). [3][4]

The recommended elemental iron dose for children is 2–3 mg/kg per day of elemental iron. This recommendation is supported by evidence from nephrology guidelines. 5
After hemoglobin has returned to normal, oral iron supplementation should be continued for approximately three months to fully replenish iron stores. This duration is endorsed by gastro‑enterology guidance. 6

For adults, the standard oral iron regimen is 200 mg of elemental iron per day, divided into 2–3 separate doses. This dosing is based on kidney disease guideline data. 5
Recent evidence indicates that lower daily elemental iron doses can achieve comparable efficacy with improved tolerability, and should be considered for patients who experience intolerance to traditional doses. This recommendation derives from gastro‑enterology research. 6

Oral iron is best absorbed when taken on an empty stomach and without concomitant medications. This principle is reflected in kidney disease recommendations. 5
Tea and coffee are potent inhibitors of iron absorption; they should be avoided for at least one hour before and after iron ingestion. This guidance comes from clinical gastroenterology studies. 7

In anemic patients, hemoglobin should rise by at least 1 g/dL within two weeks of initiating oral iron therapy. This target is supported by gastro‑enterology evidence. 7
Ferritin levels are expected to increase within one month of consistent oral iron use; failure to achieve this rise warrants consideration of intravenous iron supplementation. This monitoring recommendation is also based on gastro‑enterology data. 7

Iron polysaccharide complexes are not superior to ferrous sulfate; they are more costly and may be less effective, so ferrous sulfate remains the preferred oral formulation. This conclusion is drawn from kidney disease guideline analyses. 5